Key facts
- This page summarizes Eric Morgen's Form 4 filing for BioAge Labs, Inc. (BIOA).
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 27 Sep 2024, 16:17.
Eric Morgen - 17 Apr 2024 Form 4 Insider Report for BioAge Labs, Inc. (BIOA)
- Reporting relationship
- Chief Operating Officer, Director
- Issuer ticker
- BIOA
- Reported as of
- 17 Apr 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Sep 2024, 16:17:00 UTC
- Next SEC filing
- 25 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dov A. Goldstein as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Eric Morgen filed Form 4 for BioAge Labs, Inc. (BIOA) on 27 Sep 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BIOA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +4,952
- Change %
- Price
- $0.000000
- Shares after
- 4,952
- Date
- 25 Sep 2024
- Ownership
- By Spouse
- Underlying class
- Common Stock
- Underlying amount
- 4,952
- Exercise price
- $18.00
- Footnotes
- F1, F2
BIOA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +257,973
- Change %
- Price
- $0.000000
- Shares after
- 257,973
- Date
- 17 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 257,973
- Exercise price
- $8.39
- Footnotes
- F3, F4
BIOA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +13,598
- Change %
- Price
- $0.000000
- Shares after
- 13,598
- Date
- 17 Apr 2024
- Ownership
- By Spouse
- Underlying class
- Common Stock
- Underlying amount
- 13,598
- Exercise price
- $8.39
- Footnotes
- F2, F3, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The option shall vest as to 1/48th of the total award monthly, with the first tranche vesting on October 1, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Footnote F2
Represents an employee stock option directly held by the reporting person's spouse.
Footnote F3
This option award represents an equity security previously reported on the reporting person's Form 3, which was acquired through an exempt transaction with the Issuer prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a).
Footnote F4
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on May 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Additionally, the entire award is exercisable at any time pursuant to an early exercise feature of the option award.
Footnote F5
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on May 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.